Journal of Clinical Medicine (Apr 2022)

T<sub>1ρ</sub> for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study

  • Ernst S. Kooreman,
  • Max Tanaka,
  • Leon C. ter Beek,
  • Femke P. Peters,
  • Corrie A. M. Marijnen,
  • Uulke A. van der Heide,
  • Petra J. van Houdt

DOI
https://doi.org/10.3390/jcm11071998
Journal volume & issue
Vol. 11, no. 7
p. 1998

Abstract

Read online

Quantitative MRI has the potential to produce imaging biomarkers for the prediction of early response to radiotherapy treatment. In this pilot study, a potential imaging biomarker, the T1ρ relaxation time, is assessed for this purpose. A T1ρ sequence was implemented on a 1.5 T MR-linac system, a system that combines an MRI with a linear accelerator for radiation treatment. An agar phantom with concentrations of 1–4% w/w was constructed for technical validation of the sequence. Phantom images were assessed in terms of short-term repeatability and signal-to-noise ratio. Twelve rectal cancer patients, who were treated with 5 × 5 Gy, were imaged on each treatment fraction. Individual changes in the T1ρ values of the gross tumor volume (GTV) showed an increase for most patients, although a paired t-test comparing values in the GTV from the first to the last treatment fraction showed no statistically significant difference. The phantom measurements showed excellent short-term repeatability (0.5–1.5 ms), and phantom T1ρ values corresponded to the literature values. T1ρ imaging was implemented successfully on the MR-linac, with a repeatability comparable to diagnostic systems, although clinical benefit in terms of treatment response monitoring remains to be demonstrated.

Keywords